Enveda raised $311 million on September 23. The Series E valued the Boulder, Colorado biotech near $2 billion — double the mark it reached twelve months earlier.
Catalio Capital Management led the round. Durable Capital Partners, ICONIQ, Lightspeed and T. Rowe Price joined. In total, the company has now raised more than $845 million since 2019.
The money followed the data.
Two of the company's AI-discovered medicines posted positive early readouts in 2026, both from molecules the company found in plants and microbes rather than designed from scratch.
TIMELINE: Enveda Biosciences
─────────────────────────────────────────────────────────────
2019 ───── 2021 ───── 2024 ────── 2025 ───── 2026
🔬 💰 $51M 💰 $130M 🦄 $1B ◉ $2B
NSF grants Series A Series C Series D Series E $311M
Company funding history, 2019–2026 (source: Enveda, Business Wire)
What $845 Million Buys
Six years of work went into a single asset before the first patient was dosed: a database of nature's chemistry, built to be searched.
The platform is PRISM. It is a foundation model trained on more than a billion small-molecule mass spectra. By the company's own account, that is the largest such training set assembled — an order of magnitude beyond the previous best.
The model reads a sample, predicts which molecules it contains, and ranks them by therapeutic potential. Its chemists then refine the best candidates into oral medicines.
The starting point is what separates it from most AI drug hunters. They begin with a target and design a molecule against it. Enveda begins with molecules that evolution already shaped to act on living systems, then works backward toward a target it can name.
Natural-product hit rate, Enveda labs
Share of Enveda's natural-product scaffolds that advanced to a declared development candidate, against an industry average near 1 in 40. · Enveda, 2026
Two Pills Carrying the Case
ENV-294 is a once-daily oral pill for moderate-to-severe atopic dermatitis. Phase 1b data presented in July cut the Eczema Area and Severity Index by a mean 68% at day 28. By day 42 the reduction had deepened to 85%.
The company is now running Phase 2a trials in atopic dermatitis and asthma. That is where the effect size either holds or shrinks.
ENV-294 response in atopic dermatitis
Mean reduction in eczema area and severity in Phase 1b; it deepened to 85% by day 42. · Enveda, July 2026
ENV-308 is the more unusual bet. The company engineered it to mimic N-lactoyl-phenylalanine, a hormone the body releases after exercise. It is not a weight-loss drug. It is aimed at weight maintenance — a daily pill to help patients hold their weight after they stop a GLP-1.
Phase 1 results in healthy volunteers, reported in August, showed the drug was tolerated. A third candidate, ENV-6946 for inflammatory bowel disease, is in Phase 1.
Three shots on goal, all found by the same platform.
"We want to carry medicines from discovery through late-stage development, and do it faster and at lower cost than the industry has come to accept."— Viswa Colluru, founder and CEO, Enveda
Colluru started Enveda in 2019 after an early stint at Recursion Pharmaceuticals, another company built on reading biology with machine learning.
The Part the Round Doesn't Fix
Phase 1 data is the easiest data to get. A molecule that looks clean in a few dozen volunteers can still fail in a few thousand.
Atopic dermatitis is a crowded field. An injectable biologic set the standard, and several oral pills already compete with it. Its pill has to show efficacy that survives Phase 3, where placebo response runs high and effect sizes tend to shrink.
Metabolic drugs face a different bar. GLP-1 medicines reset what patients and physicians expect from weight loss. A maintenance pill matters only if patients cannot or will not stay on injections. That is a real market, and a narrower one.
Three Turning Points
2019–2022: building the library
2024–2025: from platform to pipeline
2026: the clinic answers back
What the Round Actually Signals
The round is the strongest example of a broader shift, not a lone one. On the same day it closed, Basecamp Research raised $140 million for AI-designed drugs, backed by Nvidia and Anthropic's Anthology Fund. In September, an in-silico drug-development method crossed the FDA's qualification threshold.
The AI-biotech cohort is moving from platform demonstrations to clinical proof. Capital is following the companies that have human data.
For the company, the valuation doubles the paper bar and lifts it too.
By a lot.
As we wrote in September, AI-designed biological matter is moving from lab curiosity to working product. Designer phage genomes were one signal. A $2 billion valuation for a company mining plants is another.
What Decides It Now
The next milestone is a Phase 2 readout, not another funding round. ENV-294's asthma and atopic dermatitis trials will show whether the platform's hit rate in the lab translates into an effect size physicians will prescribe.
ENV-308 has to prove the maintenance market is more than a thin slice of GLP-1 users who want off injections.
The eczema candidate carries the stronger evidence; obesity is the larger prize.
The next Phase 2 readout, not the next round, decides whether the model holds.
Old Chemistry, New Tools
Plants have produced aspirin, metformin and warfarin. Its argument is that most of that chemistry has never been read. Whether a 1-in-4 hit rate in the lab becomes an approval rate in the clinic is the question $845 million is still trying to answer.